Wedbush Reaffirms Outperform Rating for Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences (NASDAQ:ALPNGet Rating)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research report issued on Tuesday, RTT News reports. They presently have a $22.00 target price on the biotechnology company’s stock. Wedbush’s target price indicates a potential upside of 172.61% from the stock’s current price.

ALPN has been the topic of a number of other research reports. Oppenheimer cut their price objective on shares of Alpine Immune Sciences from $19.00 to $17.00 in a report on Monday, March 7th. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Alpine Immune Sciences in a research report on Friday.

ALPN stock traded up $0.18 during midday trading on Tuesday, hitting $8.07. The stock had a trading volume of 2,528 shares, compared to its average volume of 97,349. The firm has a market cap of $244.76 million, a PE ratio of -4.53 and a beta of 1.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.58 and a quick ratio of 2.58. Alpine Immune Sciences has a 12-month low of $6.00 and a 12-month high of $15.14. The company’s 50-day moving average price is $8.57 and its 200 day moving average price is $9.95.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last posted its earnings results on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%. As a group, sell-side analysts anticipate that Alpine Immune Sciences will post -1.09 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALPN. BlackRock Inc. grew its position in Alpine Immune Sciences by 0.7% in the 3rd quarter. BlackRock Inc. now owns 547,782 shares of the biotechnology company’s stock worth $5,844,000 after purchasing an additional 3,627 shares during the last quarter. Barclays PLC grew its position in Alpine Immune Sciences by 223.1% in the 3rd quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 3,278 shares during the last quarter. Geode Capital Management LLC grew its position in Alpine Immune Sciences by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 194,021 shares of the biotechnology company’s stock worth $2,070,000 after purchasing an additional 2,483 shares during the last quarter. Ensign Peak Advisors Inc grew its position in Alpine Immune Sciences by 33.6% in the 3rd quarter. Ensign Peak Advisors Inc now owns 72,930 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 18,350 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Alpine Immune Sciences by 11.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 50,364 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 5,064 shares during the last quarter. Hedge funds and other institutional investors own 77.00% of the company’s stock.

Alpine Immune Sciences Company Profile (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Further Reading

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.